Guangdong Biolight Meditech Co., Ltd. (SHE:300246)
China · Delayed Price · Currency is CNY 13.44
+0.50 (3.86%)
Nov 13, 2026, 3:04 PM CST
SHE:300246 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,518 | 2,119 | 1,724 | 2,725 | 2,869 | 3,192 | |
Market Cap Growth | 48.29% | 22.91% | -36.74% | -5.01% | -10.13% | -15.90% |
Enterprise Value | 3,699 | 2,230 | 2,011 | 2,906 | 2,602 | 3,246 |
Last Close Price | 13.44 | 8.10 | 6.55 | 10.24 | 10.69 | 14.14 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 129.62 | 50.04 |
Forward PE | - | 11.58 | 11.58 | 28.92 | 49.88 | 27.14 |
PS Ratio | 3.15 | 1.93 | 1.63 | 2.28 | 2.42 | 2.93 |
PB Ratio | 3.04 | 1.75 | 1.34 | 1.96 | 1.91 | 3.22 |
P/TBV Ratio | 3.64 | 2.08 | 1.58 | 2.33 | 2.40 | 4.72 |
P/OCF Ratio | 27.79 | 23.43 | - | 21.12 | 20.39 | 39.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.31 | 2.04 | 1.90 | 2.43 | 2.20 | 2.98 |
EV/EBITDA Ratio | 74.87 | 43.49 | - | 33.12 | 69.06 | 29.86 |
EV/EBIT Ratio | - | - | - | 77.76 | - | 44.71 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.43 | 0.60 | 0.50 | 0.42 | 0.28 | 0.36 |
Debt / EBITDA Ratio | 10.05 | 13.55 | 647.00 | 6.13 | 9.59 | 3.15 |
Debt / FCF Ratio | 46.00 | - | - | - | - | - |
Net Debt / Equity Ratio | 0.09 | 0.04 | -0.07 | -0.17 | -0.23 | 0.02 |
Net Debt / EBITDA Ratio | 2.29 | 0.93 | 10.90 | -2.69 | -9.35 | 0.18 |
Net Debt / FCF Ratio | 10.00 | -0.62 | 0.75 | 2.59 | 4.96 | -0.24 |
Asset Turnover | 0.46 | 0.44 | 0.42 | 0.48 | 0.57 | 0.66 |
Inventory Turnover | 2.91 | 3.13 | 3.46 | 3.87 | 4.21 | 4.30 |
Quick Ratio | 0.88 | 1.16 | 1.55 | 1.44 | 1.83 | 1.20 |
Current Ratio | 1.50 | 1.59 | 1.97 | 1.78 | 2.21 | 1.67 |
Return on Equity (ROE) | -9.66% | -5.22% | -5.23% | -4.22% | 1.97% | 6.64% |
Return on Assets (ROA) | -0.73% | -0.42% | -1.64% | 0.94% | -0.20% | 2.73% |
Return on Invested Capital (ROIC) | -2.24% | -1.36% | -5.58% | 3.25% | -0.61% | 6.85% |
Return on Capital Employed (ROCE) | -1.70% | -1.00% | -3.60% | 2.10% | -0.40% | 5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -3.31% | -3.28% | -4.14% | -2.39% | 0.77% | 2.00% |
FCF Yield | 0.31% | -3.64% | -6.52% | -3.35% | -2.48% | -2.59% |
Dividend Yield | 0.37% | - | - | - | 1.23% | 0.92% |
Payout Ratio | - | - | - | - | 184.49% | 91.47% |
Buyback Yield / Dilution | -0.77% | -0.77% | 0.51% | -1.23% | -18.96% | 0.26% |
Total Shareholder Return | -0.40% | -0.77% | 0.51% | -1.23% | -17.73% | 1.17% |